RSCM
IMRX icon

Rock Springs Capital Management’s Immuneering IMRX Stock Holding History

Rock Springs Capital Management’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,089,816
Closed -$17.6M – 138
2021
Q4 		$17.6M Hold
1,089,816
– – 0.41% 71
2021
Q3 		$28.9M Buy
+1,089,816
New +$29.3M 0.61% 53

Other funds holding IMRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Rock Springs Capital Management's IMRX Position: Q1 2022 in Review

Rock Springs Capital Management sold out of Immuneering (IMRX) in Q1 2022, closing a stake of 1,089,816 shares — an estimated $17.6M sold.

Rock Springs Capital Management first reported a position in IMRX in Q3 2021 and held it in 2 quarters. The position peaked at $28.9M in Q3 2021. 50 funds tracked by Wall St. Rank hold IMRX as of Q1 2022.

  • Rock Springs Capital Management reported no remaining Immuneering position as of Q1 2022 after selling out during the quarter.
  • Rock Springs Capital Management sold 1,089,816 Immuneering shares in Q1 2022, an estimated $17.6M.
  • Rock Springs Capital Management first reported a position in Immuneering in Q3 2021 and held it in 2 quarters.
  • Rock Springs Capital Management's Immuneering position peaked at $28.9M in Q3 2021.
  • 50 funds tracked by Wall St. Rank held Immuneering as of Q1 2022.

Based on Rock Springs Capital Management's 13F filing for Q1 2022, filed 16 May 2022.